Taiko Pharmaceutical Co.,Ltd. (TYO:4574)
Japan · Delayed Price · Currency is JPY 270.00
+1.00 (0.37%)
Aug 25, 2026, 3:30 PM JST
Taiko Pharmaceutical Income Statement
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 6,621 | 6,397 | 6,292 | 6,120 | 5,040 | 11,299 | |
Revenue Growth | 13.30% | 1.67% | 2.81% | 21.43% | -55.39% | -49.68% |
Cost of Revenue | 3,122 | 2,916 | 2,626 | 3,543 | 3,961 | 8,552 |
Gross Profit | 3,499 | 3,481 | 3,666 | 2,577 | 1,079 | 2,747 |
Selling, General & Admin | 3,070 | 3,022 | 3,036 | 3,583 | 4,157 | 7,694 |
Operating Expenses | 3,070 | 3,022 | 3,036 | 3,583 | 4,157 | 7,694 |
Operating Income | 429 | 459 | 630 | -1,006 | -3,078 | -4,947 |
Interest Expense | -3 | -5 | -8 | -8 | -10 | -6 |
Interest & Investment Income | 21 | 16 | 30 | 25 | 5 | 3 |
Currency Exchange Gain (Loss) | 38 | -2 | 39 | 31 | 59 | 50 |
Other Non Operating Income (Expenses) | 17 | 14 | -2 | -291 | -330 | -1,231 |
EBT Excluding Unusual Items | 502 | 482 | 689 | -1,249 | -3,354 | -6,131 |
Gain (Loss) on Sale of Investments | - | 347 | 6 | 193 | -82 | 60 |
Gain (Loss) on Sale of Assets | - | - | - | 76 | - | - |
Asset Writedown | -26 | -26 | -240 | -2,506 | -98 | -2,456 |
Legal Settlements | - | - | - | - | -499 | -359 |
Other Unusual Items | 140 | 154 | 111 | -78 | -837 | -2 |
Pretax Income | 616 | 957 | 566 | -3,564 | -4,870 | -8,888 |
Income Tax Expense | -72 | 34 | -332 | 47 | 25 | 706 |
Net Income | 688 | 923 | 898 | -3,611 | -4,895 | -9,594 |
Net Income to Common | 688 | 923 | 898 | -3,611 | -4,895 | -9,594 |
Net Income Growth | 66.59% | 2.78% | - | - | - | - |
Shares Outstanding (Basic) | 50 | 50 | 50 | 47 | 44 | 44 |
Shares Outstanding (Diluted) | 50 | 50 | 50 | 47 | 44 | 44 |
Shares Change | 0.11% | 0.11% | 5.96% | 8.62% | 0.21% | 0.35% |
EPS (Basic) | 13.69 | 18.37 | 17.89 | -76.25 | -112.27 | -220.51 |
EPS (Diluted) | 13.69 | 18.37 | 17.89 | -76.25 | -112.27 | -220.51 |
EPS Growth | 66.40% | 2.67% | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 360 | 523 | 205 | -404 | -2,058 | -3,071 |
Free Cash Flow Per Share | 7.16 | 10.41 | 4.08 | -8.53 | -47.20 | -70.58 |
Dividend Per Share | 3.300 | 3.300 | - | - | - | - |
Dividend Growth | - | -86.06% | - | - | - | - |
Gross Margin | 52.85% | 54.42% | 58.26% | 42.11% | 21.41% | 24.31% |
Operating Margin | 6.48% | 7.17% | 10.01% | -16.44% | -61.07% | -43.78% |
Profit Margin | 10.39% | 14.43% | 14.27% | -59.00% | -97.12% | -84.91% |
Free Cash Flow Margin | 5.44% | 8.18% | 3.26% | -6.60% | -40.83% | -27.18% |
EBITDA | 717 | 724 | 886 | -302 | -2,341 | -4,006 |
EBITDA Margin | 10.83% | 11.32% | 14.08% | -4.93% | -46.45% | -35.45% |
D&A For EBITDA | 288 | 265 | 256 | 704 | 737 | 941 |
EBIT | 429 | 459 | 630 | -1,006 | -3,078 | -4,947 |
EBIT Margin | 6.48% | 7.17% | 10.01% | -16.44% | -61.07% | -43.78% |
Effective Tax Rate | - | 3.55% | - | - | - | - |
Advertising Expenses | - | 800 | 767 | 979 | 806 | 3,005 |